On April 27, 2026, Quince Therapeutics, Inc. confirmed it has regained compliance with Nasdaq's minimum bid price requirement after its stock closed at $1.00 or higher for ten consecutive days. However, it still needs to meet the market value listing requirement by September 14, 2026.